{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:51:20Z","timestamp":1784191880203,"version":"3.55.0"},"reference-count":17,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,7,1]]},"abstract":"<jats:p>Objective. Heptavalent pneumococcal conjugate vaccine (PCV) has been shown to be safe and effective in healthy infants and children. However, little is known about its use in children who have human immunodeficiency virus (HIV) infection and are known to be at increased risk of developing pneumococcal infections. This study was conducted to evaluate the safety and immunogenicity of heptavalent PCV in infants with HIV infection.<\/jats:p>\n               <jats:p>Methods. The Pediatric AIDS Clinical Trials Group Study 292 Team randomized infants with HIV infection 2:1 to receive heptavalent PCV or placebo in a double-blinded manner. Infants were vaccinated with 3 doses at 2-month intervals, starting at ages 56 to 180 days. A booster dose was given at 15 months of age. Immunogenicity was evaluated after the third dose of vaccine, before and after the booster dose, and at 24 months of age.<\/jats:p>\n               <jats:p>Results. Thirty infants with HIV infection received PCV, and 15 received placebo. No differences in baseline characteristics were found across arms. Five severe acute reactions were experienced by 4 subjects: 3 in the PCV arm and 1 in the placebo arm; all occurred among subjects with symptomatic disease at study entry. No differences were found in the 2 arms with respect to the number or timing of new diagnoses through 24 months of age, including diagnoses of otitis media. However, when symptomatic subjects were examined separately, the first new diagnosis occurred more rapidly among PCV recipients. Three deaths, all judged to be unrelated to study vaccine, occurred during follow-up: 2 in the PCV arm and 1 in the placebo arm. The primary immunogenicity measures were based on composites of 4-fold changes in serotype-specific immunoglobulin G titers from preimmunization levels. We found a highly significant difference between the vaccine and placebo arms, with the PCV arm showing higher rates of response. Asymptomatic and symptomatic subjects who received PCV had similar immunologic responses for all serotypes.<\/jats:p>\n               <jats:p>Conclusions. This study demonstrates that heptavalent PCV was well tolerated and not associated with vaccine-associated adverse reactions. Most important, this vaccine was immunogenic in the infant with HIV infection. However, additional studies of this vaccine (or others) must pay special attention to patients with symptomatic HIV disease, as they seem to be at higher risk for adverse events to any antigen.<\/jats:p>","DOI":"10.1542\/peds.112.1.66","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:43:47Z","timestamp":1092444227000},"page":"66-73","source":"Crossref","is-referenced-by-count":56,"title":["Safety and Immunogenicity of a Heptavalent Pneumococcal Conjugate Vaccine in Infants With Human Immunodeficiency Virus Type 1 Infection"],"prefix":"10.1542","volume":"112","author":[{"given":"Sharon","family":"Nachman","sequence":"first","affiliation":[{"name":"Department of Pediatrics, State University of New York Health Science Center at Stony Brook, Stony Brook, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyeon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"King","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine J.","family":"Abrams","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Harlem Hospital Center, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Margolis","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Petru","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Children\u2019s Hospital Oakland, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Shearer","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Baylor College of Medicine, Texas Children\u2019s Hospital, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Smith","sequence":"additional","affiliation":[{"name":"Pediatric Medicine Branch, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Moye","sequence":"additional","affiliation":[{"name":"Pediatric, Adolescent, and Maternal AIDS Branch, National Institute of Child Health and Human Development, National Institutes of Health, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzette","family":"Blanchard","sequence":"additional","affiliation":[{"name":"Statistical and Data Analysis Center, Frontier Science & Technology Research Foundation, Inc, Chestnut Hill, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hawkins","sequence":"additional","affiliation":[{"name":"Pediatric ACTG Operations Center, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Bouquin","sequence":"additional","affiliation":[{"name":"Statistical and Data Management Center, Frontier Science & Technology Research Center, Amherst, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vink","sequence":"additional","affiliation":[{"name":"University of Maryland at Baltimore, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy","family":"Benson","sequence":"additional","affiliation":[{"name":"San Francisco General Hospital, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scharla","family":"Estep","sequence":"additional","affiliation":[{"name":"Pharmaceutical and Regulatory Affairs Branch, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Malinoski","sequence":"additional","affiliation":[{"name":"Lederle-Praxis Biologicals, West Henrietta, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Pediatric AIDS Clinical Trials Group Study 292 Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2003,7,1]]},"reference":[{"key":"2021121003381967000_R1","doi-asserted-by":"crossref","unstructured":"Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics.1998;101:604\u2013611","DOI":"10.1542\/peds.101.4.604"},{"key":"2021121003381967000_R2","doi-asserted-by":"crossref","unstructured":"Shinefield HR, Black S, Ray P, et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J.1999;18:757\u2013763","DOI":"10.1097\/00006454-199909000-00004"},{"key":"2021121003381967000_R3","doi-asserted-by":"crossref","unstructured":"Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J.2000;19:183\u2013186","DOI":"10.1097\/00006454-200003000-00003"},{"key":"2021121003381967000_R4","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics, Committee on Infectious Diseases. Policy statement: recommendation for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics.2000;106:362\u2013366","DOI":"10.1542\/peds.106.2.362"},{"key":"2021121003381967000_R5","unstructured":"Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children. Recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep.2000;49:1\u201338"},{"key":"2021121003381967000_R6","doi-asserted-by":"crossref","unstructured":"Dankner WM, Lindsey JC, Levin MJ. CD4 correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J.2001;20:40\u201348","DOI":"10.1097\/00006454-200101000-00008"},{"key":"2021121003381967000_R7","unstructured":"Danker W, Levin M, Nachman S, et al. Rates of opportunistic infections in HIV-infected children on Pediatric AIDS Clinical Trials Group treatment protocols in the post-protease inhibitor era. PACTG meetings, July 2001"},{"key":"2021121003381967000_R8","doi-asserted-by":"crossref","unstructured":"Farley JJ, King JC, Nair P, et al. Invasive pneumococcal disease among infected and uninfected children of mothers with human immunodeficiency virus infection. J Pediatr.1994;124:853\u2013858","DOI":"10.1016\/S0022-3476(05)83170-1"},{"key":"2021121003381967000_R9","doi-asserted-by":"crossref","unstructured":"Andiman WA, Mezger J, Shapiro E. Invasive bacterial infections in children born to women infected with human immunodeficiency virus type 1. J Pediatr.1994;124:846\u2013852","DOI":"10.1016\/S0022-3476(05)83169-5"},{"key":"2021121003381967000_R10","unstructured":"Centers for Disease Control and Prevention. Active bacterial core surveillance (ABCs) report, emerging infections program network, Streptococcus Pneumoniae. 1997\u20132000. Available at: www.cdc.gov\/ncidod\/dbmd\/abcs"},{"key":"2021121003381967000_R11","doi-asserted-by":"crossref","unstructured":"Quataert SA, Kirch CS, Wiedle LJ, et al. Assignment of weight-based antibody units to a human anti-pneumococci standard reference serum, lot 89-S. Clin Diagn Lab Immunol.1995;2:590\u2013597","DOI":"10.1128\/cdli.2.5.590-597.1995"},{"key":"2021121003381967000_R12","doi-asserted-by":"crossref","unstructured":"Quataert S, Martin D, Anderson P, et al. A multi-laboratory evaluation of an enzyme-linked immunoassay quantitating human antibodies to Streptococcus pneumoniae polysaccharides. Immunol Invest.2001;30:191\u2013297","DOI":"10.1081\/IMM-100105064"},{"key":"2021121003381967000_R13","doi-asserted-by":"crossref","unstructured":"Orange M, Gray B. Pneumococcal serotypes causing disease in children in Alabama. Pediatr Infect Dis J.1993;12:244\u2013245","DOI":"10.1097\/00006454-199303000-00015"},{"key":"2021121003381967000_R14","doi-asserted-by":"crossref","unstructured":"Ahman H, Kayhty H, Tamminen P, et al. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants. Pediatr Infect Dis.1996;2:134\u2013139","DOI":"10.1097\/00006454-199602000-00009"},{"key":"2021121003381967000_R15","doi-asserted-by":"crossref","unstructured":"Eskola J. Immunogenicity of pneumococcal conjugate vaccine. Pediatr Infect Dis J.2000;19:388\u2013393","DOI":"10.1097\/00006454-200004000-00035"},{"key":"2021121003381967000_R16","doi-asserted-by":"crossref","unstructured":"Hausdorff WP, Bryant J, Paradiso PR, et al. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin Infect Dis.2000;30:100\u2013121","DOI":"10.1086\/313608"},{"key":"2021121003381967000_R17","unstructured":"Feikin D, Elie C, Goetz M, et al. Immunologic and virologic response to a 7-valent pneumococcal conjugate vaccine and\/or 23-valent polysaccharide vaccine among HIV-infected adults [abstract 48]. Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2000"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/112\/1\/66\/1002273\/pe0703000066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/112\/1\/66\/1002273\/pe0703000066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T10:34:50Z","timestamp":1639132490000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/112\/1\/66\/63360\/Safety-and-Immunogenicity-of-a-Heptavalent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7,1]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2003,7,1]]},"published-print":{"date-parts":[[2003,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.112.1.66","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7,1]]}}}